0001178879-25-000011 Sample Contracts
SECOND AMENDMENT TO LOAN AGREEMENTLoan Agreement • July 31st, 2025 • Amicus Therapeutics, Inc. • Pharmaceutical preparations
This SECOND AMENDMENT TO LOAN AGREEMENT, dated as of June 16, 2025 (this “Amendment”), is entered into among AMICUS THERAPEUTICS, INC., a Delaware corporation, as the Borrower (on its own behalf and on behalf of each other Credit Party), the Lenders party hereto, and WILMINGTON TRUST, NATIONAL ASSOCIATION, as the Agent.
STOCK OPTION AWARD AGREEMENTStock Option Award Agreement • July 31st, 2025 • Amicus Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This STOCK OPTION AWARD AGREEMENT (this “Agreement”) is made by and between Amicus Therapeutics, Inc., a Delaware corporation (the “Company”), and [ ] (the “Optionee”) under the Company’s 2025 Equity Incentive Plan (the “Plan”), a copy of which is available in the Optionee’s on-line account. Capitalized terms used herein without definition shall have the meaning ascribed to such terms in the Plan.
RESTRICTED STOCK UNIT AWARD AGREEMENTRestricted Stock Unit Award Agreement • July 31st, 2025 • Amicus Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS RESTRICTED STOCK UNIT AWARD AGREEMENT (this “Agreement”) is made by and between Amicus Therapeutics, Inc., a Delaware corporation (the “Company”), and [ ] (the “Participant”) under the Company’s 2025 Equity Incentive Plan (the “Plan”), a copy of which is available in the Participant’s on-line account. Capitalized terms used herein without definition shall have the meaning ascribed to such terms in the Plan.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS OF THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LICENSE AGREEMENTLicense Agreement • July 31st, 2025 • Amicus Therapeutics, Inc. • Pharmaceutical preparations • New York
This License Agreement (this “Agreement”) is made as of May 1, 2025 (the “Effective Date”), by and between Dimerix Bioscience Pty Ltd., a company incorporated under the laws of Australia, having its principal place of business at 425 Smith St. Fitzroy 3065, Victoria, Australia (“Dimerix”), and Amicus Therapeutics, Inc., a Delaware corporation having an office at 47 Hulfish St., Princeton, NJ 08542 (“Licensee”). Licensee and Dimerix are referred to in this Agreement individually as a “Party” and collectively as the “Parties”.